Open AccessA phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis
Author(s) -
Sheng Lu,
Zhongyi Yang,
Chao Yan,
Wentao Liu,
Zhentian Ni,
Xuexin Yao,
Zichen Hua,
Runhua Feng,
Yanan Zheng,
Zhenqiang Wang,
Birendra Kumar Sah,
Mingmin Chen,
Zhonglin Zhu,
Changyu He,
Chen Li,
Min Yan,
Zhenggang Zhu
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-1414
Subject(s) - medicine , regimen , chemotherapy , paclitaxel , oncology , metastasis , cancer , randomized controlled trial , hyperthermic intraperitoneal chemotherapy , surgery , ovarian cancer , cytoreductive surgery
Although recent advances in systemic chemotherapy have improved the clinical outcomes of gastric cancer patients with peritoneal metastasis, the peritoneum still represents a common site of treatment failure and disease recurrence. Neoadjuvant intraperitoneal–systemic chemotherapy has been acknowledged as a more aggressive treatment for gastric cancer patients with peritoneal metastasis. In this multicenter phase III randomized controlled trial, 238 patients will be randomly separated into two groups in a 2:1 ratio after laparoscopic exploration. The experimental arm will receive the proposed neoadjuvant intraperitoneal–systemic chemotherapy regimen, whereas the control group will receive a Paclitaxel + S-1 (PS) chemotherapy regimen. The endpoints for the study are overall survival, response rate, gastrectomy radicality rate, progression-free survival and adverse events.